Current Allergy and Asthma Reports

, Volume 13, Issue 4, pp 371–380

Recombinant Allergen Immunotherapy: Clinical Evidence of Efficacy—A Review

  • Melina Makatsori
  • Oliver Pfaar
  • Ramon Lleonart
  • Moises A. Calderon


Recombinant allergens for immunotherapy aim to overcome the problems of natural extracts as they can be produced in unlimited amounts with exact physiochemical and immunological properties. These can be modified to have more favourable characteristics including reduced IgE reactivity or enhanced immunogenicity. Different types of recombinant allergens have been evaluated in clinical phase II and III trials whilst others are currently under development. In this review, we identified double-blind, placebo-controlled randomised clinical trials assessing the efficacy and safety of various recombinant allergen preparations. The majority of studies have up to now focused on cat, grass, birch, ragweed and bee venom allergens. Some studies have shown some of these preparations to be effective and well tolerated. However, there are still outstanding issues regarding optimum doses, minimising side effects and long-term effects.


Allergy Rhinitis Asthma Recombinants T-cell epitopes Wild-type recombinants Modified/hypoallergen allergens Fusion proteins Cat Grass Birch Ragweed Venom allergy Immunotherapy Efficacy 


  1. 1.
    Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;8, CD001186.PubMedGoogle Scholar
  2. 2.
    Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;1, CD001936.PubMedGoogle Scholar
  3. 3.
    Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis. Clin Ther. 2000;22:351–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Watanabe AS, Fonseca LA, Galvão CE, Kalil J, Castro FF. Specific immunotherapy using Hymenoptera venom: systematic review. Sao Paulo Med J. 2010;128:30–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. 2012;10, CD008838.PubMedGoogle Scholar
  6. 6.
    Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;12, CD002893.PubMedGoogle Scholar
  7. 7.
    Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy. 2011;41:1263–72.PubMedCrossRefGoogle Scholar
  8. 8.
    Cox L, Compalati E, Kundig T, Larche M. New directions in immunotherapy. Curr Allergy Asthma Rep. 2013;13:178–95.PubMedCrossRefGoogle Scholar
  9. 9.
    Focke-Tejkl M, Valenta R. Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol. 2012;12:555–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Cox L, Calderón M, Pfaar O. Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations. Immunotherapy. 2012;4:601–16.PubMedCrossRefGoogle Scholar
  11. 11.
    Cromwell O, Häfner D, Nandy A. Recombinant allergens for specific immunotherapy. J Allergy Clin Immunol. 2011;127:865–72.PubMedCrossRefGoogle Scholar
  12. 12.
    Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol. 2007;119:826–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Valenta R, Niespodziana K, Focke-Tejkl M, Marth K, Huber H, Neubauer A, et al. Recombinant allergens: what does the future hold? J Allergy Clin Immunol. 2011;127:860–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Pauli G, Malling H-J. The current state of recombinant allergens for immunotherapy. Curr Opin Allergy Clin Immunol. 2010;10:575–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Valenta R, Linhart B, Swoboda I, Niederberger V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy. 2011;66:775–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Linhart B, Valenta R. Vaccines for allergy. Curr Opin Immunol. 2012;24:354–60.PubMedCrossRefGoogle Scholar
  17. 17.
    Edlmayr J, Niespodziana K, Linhart B, Focke-Tejkl M, Westritschnig K, Scheiblhofer S, et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol. 2009;182:6298–306.PubMedCrossRefGoogle Scholar
  18. 18.
    Marth K, Breyer I, Focke-Tejkl M, Blatt K, Shamji MH, Layhadi J, et al. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J Immunol. 2013;190:3068–78.PubMedCrossRefGoogle Scholar
  19. 19.
    Larché M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol. 2007;119:906–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol. 1999;93:222–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Norman PS, Ohman JL, Long AA, Creticos PS, Gefter MA, Shaked Z, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 1996;154:1623–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Pene J, Desroches A, Paradis L, Lebel B, Farce M, Nicodemus CF, et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol. 1998;102:571–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol. 1996;8:1937–45.PubMedCrossRefGoogle Scholar
  24. 24.
    Haselden BM, Larché M, Meng Q, Shirley K, Dworski R, Kaplan AP, et al. Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. J Allergy Clin Immunol. 2001;108:394–401.PubMedCrossRefGoogle Scholar
  25. 25.
    Oldfield WL, Kay AB, Larche M. Allergen-derived T cell peptide-induced late asthmatic reac- tions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol. 2001;167:1734–39.PubMedGoogle Scholar
  26. 26.
    Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet. 2002;360:47–53.PubMedCrossRefGoogle Scholar
  27. 27.
    Smith TR, Alexander C, Kay AB, Larche M, Robinson DS. Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double-blind placebo-controlled study. Allergy. 2004:1097–101.Google Scholar
  28. 28.
    Worm M, Hae-Hyuk L, Kleine-Tebbe J, Hafner R, Laidler P, Healey D, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011;127:89–97.PubMedCrossRefGoogle Scholar
  29. 29.
    Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larché M, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131:103–9.e1-7.PubMedGoogle Scholar
  30. 30.
    Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, Leimgruber A, et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol. 2003;111:854–61.PubMedCrossRefGoogle Scholar
  31. 31.
    Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116:608–13.PubMedCrossRefGoogle Scholar
  32. 32.
    Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008;122:951–60.PubMedCrossRefGoogle Scholar
  33. 33.
    Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 2004;101:14677–82.PubMedCrossRefGoogle Scholar
  34. 34.
    Purohit A, Niederberger V, Kronqvist M, Horak F, Grönneberg R, Suck R, et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy. 2008;38:1514–25.PubMedCrossRefGoogle Scholar
  35. 35.
    Larenas-Linnemann D. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. Curr Opin Investig Drugs. 2010;11:586–96.PubMedGoogle Scholar
  36. 36.
    Rak S, De Blay F, Worm M, Robin B, Melac M, Malling HJ. Efficacy and safety of recombinant Bet v 1 (rBet v 1) tablets in sublingual immunotherapy. Allergy 2009. Abstract Presented at 27th Congress, EAACI 2009.Google Scholar
  37. 37.
    Meyer W, Narkus A, Salapatek AM, Häfner D. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Allergy. 2013 Apr 27. doi: 10.1111/all.12148. [Epub ahead of print]
  38. 38.
    Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol. 2004;113:235–41.PubMedCrossRefGoogle Scholar
  39. 39.
    Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al. Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355:1445–55.PubMedCrossRefGoogle Scholar
  40. 40.
    Pfaar O, Cazan D, Klimek L, Larenas-Linnemann D, Calderon MA. Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol. 2012;12:648–57.PubMedCrossRefGoogle Scholar
  41. 41.
    Niespodziana K, Focke-Tejkl M, Linhart B, Civaj V, Blatt K, Valent P, et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol. 2011;127:1562–70.PubMedCrossRefGoogle Scholar
  42. 42.
    Vrtala S, Fohr M, Campana R, Baumgartner C, Valent P, Valenta R. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine. 2011;29:2140–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Muller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998;101:747–54.PubMedCrossRefGoogle Scholar
  44. 44.
    Texier C, Pouvelle S, Busson M, Herve M, Charron D, Menez A, et al. HLADR restricted peptide candidates for bee venom immunotherapy. J Immunol. 2000;164:3177–84.PubMedGoogle Scholar
  45. 45.
    Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy. 2006;36:465–74.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Melina Makatsori
    • 1
  • Oliver Pfaar
    • 2
  • Ramon Lleonart
    • 3
  • Moises A. Calderon
    • 1
  1. 1.Section of Allergy and Clinical Immunology, Imperial College LondonNHLI, Royal Brompton HospitalLondonUK
  2. 2.Centre for Rhinology and Allergology Wiesbaden, Department of Otorhinolaryngology, Head and Neck SurgeryUniversity HospitalMannheimGermany
  3. 3.Allergy Unit, Internal Medicine DepartmentHospital Universitari de BellvitgeBarcelonaSpain

Personalised recommendations